David Piwnica-Worms

Last updated

David Piwnica-Worms is an American radiologist and biochemist. He is the Gerald Dewey Dodd Jr., Endowed Distinguished Chair in Diagnostic Imaging and a professor of Cancer Systems Imaging and Professor of Cancer Biology at The University of Texas MD Anderson Cancer Center. He also serves as the chair of the Department of Cancer Systems Imaging at the same institution.

Contents

Career and research work

Piwnica-Worms earned his bachelor's degree from Stanford University and his medical and doctorate degrees from Duke University School of Medicine, where he was a Medical Scientist Training Program awardee. Piwnica-Worms completed his residency in diagnostic radiology and a fellowship at Brigham and Women’s Hospital, followed by faculty appointments at Harvard Medical School. He spent two decades at Washington University School of Medicine in St. Louis, where he directed the Molecular Imaging Center and the BRIGHT Institute before joining MD Anderson Cancer Center in 2013. [1]

A pioneer in the field of molecular imaging Piwnica-Worms has developed innovative methods to visualize and measure biological processes in living organisms at the molecular and cellular levels. His work primarily involves genetically encoded bioluminescent and radiotracer reporter systems to study signal transduction, protein interactions, and gene expression in various biological contexts, including single cells, cell populations, and live animals. [2]

His past research interests also included the function and regulation of the multidrug resistance P-glycoprotein family of transporters. He currently leads translational research efforts using cell-penetrating peptides for fluorescence imaging applications in the eye. [3] [4] and radiopharmaceuticals for medical imaging applicationsof inflammation with. positron emission tomography (PET). [5] His lab has also discovered and is advancing novel ligands and antibodies into the clinic for imaging and beta-radioligand therapy applications (theranostics) targeting B7H3, a receptor expressed on many tumors.

He is a scientific founder of Radiopharm Ventures. [6]

Honors

Personal life

Born in 1956, Piwnica-Worms is married to cell-cycle researcher Helen Piwnica-Worms. [10] They have a daughter and a son.

Related Research Articles

Richard D. Cummings is an American biochemist who is the S. Daniel Abraham Professor of Surgery at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, Massachusetts. He also the chief of the division of surgical sciences within the department of surgery. He is the director of the Harvard Medical School Center for Glycoscience, director of the National Center for Functional Glycomics, and also founder of the Glycomics Core at BIDMC. As of 2018 Cummings is also the scientific director of the Feihi Nutrition Laboratory at BIDMC. Before moving to BIDMC/HMS, Cummings was the William Patterson Timmie Professor and chair of the department of biochemistry at Emory University School of Medicine in Atlanta, Georgia from 2006 to 2015. At Emory, Cummings was a founder in 2007 of the Emory Glycomics Center.

<span class="mw-page-title-main">Lutetium(III) chloride</span> Chemical compound

Lutetium(III) chloride or lutetium trichloride is the chemical compound composed of lutetium and chlorine with the formula LuCl3. It forms hygroscopic white monoclinic crystals and also a hygroscopic hexahydrate LuCl3·6H2O. Anhydrous lutetium(III) chloride has the YCl3 (AlCl3) layer structure with octahedral lutetium ions.

<span class="mw-page-title-main">Jonathan Simons</span> American oncologist

Jonathan W. Simons is an American physician-scientist, medical oncologist, and leader in prostate cancer research. In August 2021, Simons was appointed the medical director and Chief Science Officer of the Marcus Foundation. Prior to joining the Marcus Foundation, he served a 14-year tenure as the President and chief executive officer of the Prostate Cancer Foundation. Simons’ laboratories, partly funded by the Prostate Cancer Foundation, at Johns Hopkins University and Emory University made original contributions to understanding the molecular biology of prostate cancer metastasis and principles of “broken immune tolerance” via T cell based immunotherapy for prostate cancer. The Simons lab invented GM-CSF genetically engineered vaccines for prostate cancer in rodents and humans for these studies, and subsequently Simons’ clinical team took the biotechnology into the world’s first human gene therapy clinical trials for advanced prostate cancer at Johns Hopkins.

Alan D. D'Andrea is an American cancer researcher and the Fuller American Cancer Society Professor of Radiation Oncology at Harvard Medical School. D'Andrea's research at the Dana Farber Cancer Institute focuses on chromosome instability and cancer susceptibility. He is currently the director of the Center for DNA Damage and Repair and the director of the Susan F. Smith Center for Women's Cancer.

<span class="mw-page-title-main">James P. Allison</span> American immunologist and Nobel laureate (born 1948)

James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center in Houston, Texas. Allison is Regental Professor and Founding-Director of James P. Allison Institute at the MD Anderson Cancer Center.

<span class="mw-page-title-main">European Association of Nuclear Medicine</span>

The European Association of Nuclear Medicine (EANM) is the leading professional organisation for nuclear medicine in Europe. Established in 1985, the EANM serves as an umbrella organisation comprising national societies, affiliated societies and individual members working in nuclear medicine or related fields. It is also dedicated to the promotion of nuclear medicine amongst other medical learned societies, EU institutions like the European Union, international organisations like the International Atomic Energy Agency, and the general public.

<span class="mw-page-title-main">Sanjiv Sam Gambhir</span> American physician–scientist (1962–2020)

Sanjiv Sam Gambhir was an American physician–scientist. He was the Virginia and D.K. Ludwig Professor in Cancer Research, Chairman of the Department of Radiology at Stanford University School of Medicine, and a professor by courtesy in the departments of Bioengineering and Materials Science and Engineering at Stanford University. Additionally, he served as the Director of the Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection and the Precision Health and Integrated Diagnostics Center (PHIND). He authored 680 publications and had over 40 patents pending or granted. His work was featured on the cover of over 25 journals including the Nature Series, Science, and Science Translational Medicine. He was on the editorial board of several journals including Nano Letters, Nature Clinical Practice Oncology, and Science Translational Medicine. He was founder/co-founder of several biotechnology companies and also served on the scientific advisory board of multiple companies. He mentored over 150 post-doctoral fellows and graduate students from over a dozen disciplines. He was known for his work in molecular imaging of living subjects and early cancer detection.

<span class="mw-page-title-main">Don W. Cleveland</span> American cancer biologist and neurobiologist

Don W. Cleveland is an American cancer biologist and neurobiologist.

Samuel Achilefu is a Nigerian-born scientist and medical researcher who has pioneered both fundamental and applied research in science, engineering, and medicine. Dr. Samuel Achilefu is Professor and Chair of the Department of Biomedical Engineering at the University of Texas Southwestern Medical Center, where he holds the Lyda Hill Distinguished University Chair in Biomedical Engineering. He is also Professor of Radiology and a member of the Simmons Comprehensive Cancer Center. Before joining UT Southwestern, he was the Michel M. Ter-Pogossian Professor of Radiology and Vice Chair for Innovation and Entrepreneurship at the Mallinckrodt Institute of Radiology, Washington University School of Medicine. He held joint appointments as a professor of medicine, biochemistry and molecular biophysics, and biomedical engineering. He also served as the Director of the Washington University Molecular Imaging Center and the privately funded Theranostic Innovation Program and was co-director of the Center for Multiple Myeloma Nanotherapy and co-Leader of the Oncologic Imaging Program of the Alvin J. Siteman Cancer Center at Washington University.

<span class="mw-page-title-main">Robert H. Singer</span> American cell biologist

Dr. Robert H. Singer received an undergraduate degree in physical chemistry from Oberlin College, and a PhD in developmental biology from Brandeis University. He did postdoctoral work in molecular biology at the Massachusetts Institute of Technology and the Weizmann Institute of Science in Rehovot, Israel. Oberlin College granted Singer an Honorary Doctor of Science in 2016. The Hebrew University of Jerusalem granted Singer an Honorary Doctorate in 2018.

Michael Green was an American molecular biologist and cell biologist at the University of Massachusetts Medical School, where he was the chair of the Department of Molecular, Cell and Cancer Biology, director of the UMass Cancer Center, and a Howard Hughes Medical Institute investigator. Green was a member of the National Academy of Sciences and the National Academy of Medicine.

Michael C. Ostrowski is an American cancer biologist and geneticist currently is the WH Folk Endowed Professor at Hollings Cancer Center, Medical University of South Carolina and an Elected Fellow at the American Association for the Advancement of Science. His interests are cancer cells and genes.

Anna Huttenlocher is an American cell biologist and physician-scientist known for her work in cell migration and wound healing.

Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.

Yusuf Awni Hannun is an American molecular biologist, biochemist, and clinician. He is known for the discovery that sphingolipids have signaling functions.

Zhimin (James) Lu is a Chinese-American biologist and oncologist. He is a professor, Kuancheng Wang Distinguished Chair, and Dean of Institute of Translational Medicine at Zhejiang University. Prior to joining Zhejiang University in 2019, he was the Ruby E. Rutherford Distinguished Professor and the director of Cancer Metabolism Program at the University of Texas MD Anderson Cancer Center.

Eric Reese Fearon is an American oncologist. He is the Emanuel N. Maisel Professor of Oncology at the University of Michigan and director of the University of Michigan Rogel Cancer Center.

Helen Margaret Piwnica-Worms is an American cell-cycle researcher. Since 2013, she has served as vice provost of science at the MD Anderson Cancer Center and professor in MD Anderson's Department of Cancer Biology.

<span class="mw-page-title-main">Sendurai Mani</span>

Sendurai A. Mani is an Indian-American oncologist and a Molecular Biologist. He is a fellow of the American Association for the Advancement of Sciences, and Dean's Chair for Translational Oncology at Brown University Warren Alpert Medical School. He is also the associate director for Translational Oncology at the Legorreta Cancer Center at Alpert Medical School, Brown University. Previously, he was a co-director of Metastasis Research Center and co-director, the Center for Stem Cell & Developmental Biology, and a professor of Translational Molecular Pathology at MD Anderson Cancer Center.

Theranostics, also known as theragnostics, is a technique commonly used in personalised medicine. For example in nuclear medicine, one radioactive drug is used to identify (diagnose) and a second radioactive drug is used to treat (therapy) cancerous tumors. In other words, theranostics combines radionuclide imaging and radiation therapy which targets specific biological pathways.

References

  1. ↑ "MD Anderson names Piwnica-Worms as chair". AuntMinnie. 18 February 2013.
  2. ↑ "Monitoring Inflammation Using a Redox-Tuned Reporter". GEN - Genetic Engineering and Biotechnology News. 23 February 2022.
  3. ↑ Dryden, Jim (2 April 2004). "Agent reveals drug-resistant cancer". washu.edu.
  4. ↑ https://www.jbc.org/article/S0021-9258(18)36963-1/pdf
  5. ↑ "Monitoring Inflammation Using a Redox-Tuned Reporter". GEN. 23 February 2022.
  6. ↑ "MD Anderson and Radiopharm Theranostics launch joint venture to develop novel radiopharmaceuticals". MD Anderson Cancer Center.
  7. ↑ "Institute of Medicine Elects 70 New Members, 10 Foreign Associates". ASCO Post.
  8. ↑ "New AAAS Fellows Recognized for Their Contributions to Advancing Science | American Association for the Advancement of Science (AAAS)". AAAS.
  9. ↑ "Fellows". World Molecular Imaging Society. 23 August 2013.
  10. ↑ "Why I Give: Learn More About TAMEST Members DRS. Helen and David Piwnica-Worms".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.